Last reviewed · How we verify
Conventional NSAA
Conventional NSAA (non-selective androgen antagonist) blocks androgen receptor signaling to suppress testosterone-driven prostate cancer growth.
Conventional NSAA (non-selective androgen antagonist) blocks androgen receptor signaling to suppress testosterone-driven prostate cancer growth. Used for Advanced prostate cancer (metastatic castration-resistant or castration-sensitive).
At a glance
| Generic name | Conventional NSAA |
|---|---|
| Sponsor | University of Sydney |
| Drug class | Androgen receptor antagonist |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NSAAs are non-selective antagonists that bind to the androgen receptor and inhibit its activation by androgens (testosterone and DHT), thereby suppressing androgen-dependent transcription in prostate cancer cells. This mechanism is distinct from selective AR antagonists and is used in androgen deprivation therapy for advanced prostate cancer. The conventional formulation represents earlier-generation AR antagonist technology compared to newer selective agents.
Approved indications
- Advanced prostate cancer (metastatic castration-resistant or castration-sensitive)
Common side effects
- Hot flashes
- Gynecomastia
- Fatigue
- Hepatotoxicity
- Gastrointestinal disturbance
Key clinical trials
- Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (PHASE3)
- Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional NSAA CI brief — competitive landscape report
- Conventional NSAA updates RSS · CI watch RSS
- University of Sydney portfolio CI